Accordingly, T2DM patients who used insulin analogs such as glargine exhibited a high risk of cancer in a dose-dependent manner (adjusted hazard ratio was 1.1, 1.2, and 1.3 for daily doses of 10, 30, and 50 U, respectively) (Jalving et al., 2010). Here, INS is linked to cancer.